Docoh
Loading...

AERI Aerie Pharmaceuticals

APP
Utility
Isoquinoline-steroid Conjugates and Uses Thereof
30 Sep 21
Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases.
Mitchell A. deLong, Eric Carlson, Casey Kopczynski, Jill M. Sturdivant, Cynthia Lichorowic
Filed: 4 Jun 21
GRANT
Utility
Intravitreal drug delivery systems for the treatment of ocular conditions
14 Sep 21
The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems.
Stuart Williams, Sanjib Kumar Das, Tomas Navratil, Melissa Sandahl, Janet Tully, Rozemarijn Verhoeven
Filed: 12 Dec 19
GRANT
Utility
Compounds, compositions and methods for treatment of myopia
14 Sep 21
Provided herein are 8-methyl-8-azabicyclo[3.2.1]octan-3-yl and pyridin-4-ylmethanyl ester and amide compounds and compositions.
Eric Carlson, Mitchell A. deLong, Heeren Gordhan, Cynthia L. Lichorowic, Jill M. Sturdivant
Filed: 31 Jan 20
APP
Utility
Beta- and Gamma-amino-isoquinoline Amide Compounds and Substituted Benzamide Compounds
19 Aug 21
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds.
Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Filed: 29 Apr 21
APP
Utility
Compositions for Treating Glaucoma or Reducing Intraocular Pressure
12 Aug 21
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure.
Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
Filed: 23 Apr 21
APP
Utility
Combination Therapy
5 Aug 21
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure.
Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
Filed: 23 Apr 21
GRANT
Utility
Isoquinoline-steroid conjugates and uses thereof
13 Jul 21
Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases.
Mitchell A. deLong, Eric Carlson, Casey Kopczynski, Jill M. Sturdivant, Cynthia Lichorowic
Filed: 30 Aug 19
GRANT
Utility
Dual mechanism inhibitors for the treatment of disease
8 Jun 21
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition.
Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Filed: 30 Dec 19
GRANT
Utility
Combination therapy
1 Jun 21
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure.
Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
Filed: 30 Dec 19
GRANT
Utility
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
1 Jun 21
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds.
Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Filed: 30 Dec 19
APP
Utility
Amino-benzoisothiazole and Amino-benzoisothiadiazole Amide Compounds
25 Mar 21
Provided herein are amino-benzoisothiazole and benzoisothiadiazole amide compounds.
Mitchell A. deLong, Jill M. Sturdivant, Cynthia L. Lichorowic
Filed: 14 Mar 19
GRANT
Utility
6-aminoisoquinoline compounds
26 Jan 21
6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase.
Mitchell A. deLong, Susan M. Royalty, Jill Marie Sturdivant, Geoffrey Richard Heintzelman
Filed: 11 Nov 19
APP
Utility
Aryl Cyclopropyl-amino-isoquinolinyl Amide Compounds
6 Jan 21
Provided herein are arylcyclopropyl amino-isoquinoline amide compounds.
Mitchell A. deLong, Jill M. Sturdivant, Cynthia L. Lichorowic, Andriy Kornilov
Filed: 21 Jul 20
GRANT
Utility
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
4 Jan 21
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds.
Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Filed: 11 Dec 19
GRANT
Utility
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
7 Dec 20
Provided herein are arylcyclopropyl amino-isoquinoline amide compounds.
Mitchell A. deLong, Jill M. Sturdivant, Cynthia L. Lichorowic, Andriy Kornilov
Filed: 29 Mar 18
GRANT
Utility
Implant applicators and methods of administering implants
30 Nov 20
Embodiments described herein relate generally to medical implant delivery apparatuses and methods.
Tomas Navratil, Jessie Delgado, Michael Hunter
Filed: 4 Sep 17
APP
Utility
Pharmaceutical Compositions for Treating Ocular Diseases or Disorders
30 Sep 20
Provided herein are pharmaceutical compositions, intravitreal implants and particle suspensions comprising a polymer matrix and at lest one therapeutic agent that is released in a substantially linear manner for a particular duration.
Sanjib Kumar Das, Cheng-Wen Lin
Filed: 4 Mar 20
APP
Utility
Ophthalmic composition for treating dry eye and symptoms thereof
30 Sep 20
It is provided an ophthalmic composition, particularly formulated as eye drops, comprising a non-ionic surfactant as active ingredient, wherein the non-ionic surfactant is present in an effective amount from 0.01 to 8 weight/volume % based on the total composition, for use in treating or preventing dry eye and/or for relieving one or more symptoms and/or signs of dry eye.
Francisco Javier Galan Valdivia
Filed: 5 Mar 20
APP
Utility
Combination Therapy
2 Sep 20
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure.
Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
Filed: 2 Feb 20
APP
Utility
Compounds, Compositions and Methods for Treatment of Myopia
5 Aug 20
Provided herein are 8-methyl-8-azabicyclo[3.2.1]octan-3-yl and pyridin-4-ylmethanyl ester and amide compounds and compositions.
Eric Carlson, Mitchell A. deLong
Filed: 30 Jan 20
Patents are sorted by USPTO publication date, most recent first